NEW YORK — New York Blood Center Enterprises (NYBCe) today announced the addition of Jung E. Choi and Jaime Shamonki, MD to its Board of Trustees. The two highly-accomplished executives bring decades of experience in the life science and biopharmaceutical fields, that will help evolve NYBCe into its next chapter as an integrated research, development and commercial organization focused on transfusion medicine, benign hematologic disorders, cellular therapies and infectious diseases.
“We are thrilled to have Ms. Choi and Dr. Shamonki join our Board,” said Christopher D. Hillyer, MD, President and CEO, of NYBCe. “Both executives have the expertise to help us navigate and capitalize on our many opportunities for accelerating NYBCe’s research, business development and venture initiatives.”
“It is a real honor to join the leaders of this prestigious institution, dedicated to saving lives through blood products and innovative research,” said Jung E. Choi. “I look forward to working with my fellow Board members and the Management team to find new ways to further expand NYBCe’s reach and increase its impact on the communities it serves.”
“At the start of my career, I trained in transfusion medicine at New York Blood Center and I am proud to once again be part of their amazing team as a member of NYBCe’s Board,” said Jaime Shamonki, MD. “Together, we will work to further NYBCe’s lifesaving mission to provide the highest quality research, services and technologies in the fields of hematology and other important therapeutic areas.”
Jung E. Choi is the Chief Business and Strategy Officer at Global Blood Therapeutics Inc. (NASDAQ: GBT), a biopharmaceutical company discovering, developing, and delivering treatments for grievous blood disorders, including sickle cell disease. At GBT, Ms. Choi spearheads the company’s business development activities and corporate strategy, as well as oversees patient advocacy, government affairs, and program team leadership for inclacumab, a late stage clinical candidate for sickle cell disease.
Jaime Shamonki, MD is the Chief Medical Officer of Generate Life Sciences, a life sciences company helping to grow and protect families through reproductive, newborn stem cell, genetic screening, medical device and healthcare technology services. As a life sciences senior executive, Dr. Shamonki has directly contributed to significant corporate growth by introducing numerous innovations and new services that elegantly reinforce value to the customer and support enterprise through adjacent business development opportunities.